Triple
T15982913
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Vertex Pharmaceuticals |
E387617
|
entity |
| Predicate | regulatoryApprovalFor |
P24602
|
FINISHED |
| Object | Trikafta |
E1188104
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Trikafta | Statement: [Vertex Pharmaceuticals, regulatoryApprovalFor, Trikafta]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Trikafta Context triple: [Vertex Pharmaceuticals, regulatoryApprovalFor, Trikafta]
-
A.
Trikafta
chosen
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
Skyrizi
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d86da94ccc819083d187f5dc6a123e |
completed | April 10, 2026, 3:25 a.m. |
| NER | Named-entity recognition | batch_69e15755b5548190acfa29eecb11e675 |
completed | April 16, 2026, 9:40 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ffcf1abad48190a42510605c30d0b3 |
completed | May 10, 2026, 12:19 a.m. |
Created at: April 10, 2026, 4:54 a.m.